サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467904

うっ血性心不全治療薬市場：薬剤クラス別、投与経路別、流通チャネル別、地域別、2024～2032年

Congestive Heart Failure Drugs Market by Drug Class, Route of Administration, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
うっ血性心不全治療薬市場：薬剤クラス別、投与経路別、流通チャネル別、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のうっ血性心不全治療薬の市場規模は2023年に85億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに226億米ドルに達し、2024～2032年の間に11.17%の成長率（CAGR）を示すと予測しています。肥満や心血管疾患の有病率の上昇、高齢者人口の増加、不健康な食習慣などが市場を牽引する主要要因です。

うっ血性心不全は、心筋のポンプ機能に影響を及ぼす病状です。一般に、高血圧、冠動脈疾患、糖尿病、肥満、過度のアルコール摂取が原因となります。その症状には、横になっているときの息切れ、脱力感、疲労感、腹部、足、足首のむくみ、夜間の頻尿、吐き気、集中力の低下などがあります。健康的な体重を維持し、身体を活発に動かし、血圧や血糖値をコントロールすることで予防できます。このほか、血栓を防ぎ、血管を拡大し、心臓の収縮を強化し、心臓の機能を改善するさまざまな処方薬を使ってコントロールします。現在、最も処方されているうっ血性心不全治療薬としては、ACE阻害薬、血管拡大薬、ジギタリス配糖体、利尿薬、β遮断薬などがあります。このうち、ACE阻害薬は血管を収縮させるアンジオテンシンの生成を防ぎ、β遮断薬は特定の化学物質の作用を阻害します。

現在、糖尿病や慢性心血管系疾患に罹患しやすい世界の高齢者人口の増加が、市場にプラスの影響を与える主要要因の一つとなっています。加えて、過度の喫煙やアルコール飲料の飲酒は、個人の不健康な食習慣と相まって心臓疾患のリスクを増大させ、これが世界中でうっ血性心不全治療薬の需要を喚起しています。このことは、肥満や運動不足による心臓疾患の発生率の上昇と相まって、現在、市場の成長を強化しています。さらに、心臓病の早期診断と治療薬の利点に関する個人の意識の高まりが、市場に明るい展望をもたらしています。これとは別に、効果的な薬剤や治療薬法に対する需要の高まりと、認可機関からの承認は、主要な市場参入企業に有利な成長機会を提供しています。さらに、医療インフラを改善し、患者に最適なケアを提供するために各国政府が行っている取り組みが、市場の成長に寄与しています。さらに、病院や住宅地での薬局の拡大や、手頃な価格で医薬品を簡単に入手できる急成長中のeコマース産業、安全なオンライン決済方法の設備は、市場の成長を促進すると期待されています。

本レポートで扱う主要質問

  • 世界のうっ血性心不全治療薬市場の規模は？
  • 2024～2032年の世界のうっ血性心不全治療薬市場の予想成長率は？
  • 世界のうっ血性心不全治療薬市場を牽引する主要因は何か？
  • COVID-19が世界のうっ血性心不全治療薬市場に与えた影響は？
  • 薬剤クラス別にみた世界のうっ血性心不全治療薬市場の内訳は？
  • 投与経路別のうっ血性心不全治療薬の世界市場内訳は？
  • うっ血性心不全治療薬の世界市場における販売チャネル別の内訳は？
  • うっ血性心不全治療薬の世界市場における主要地域は？
  • うっ血性心不全治療薬の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のうっ血性心不全治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • ACE阻害剤
  • アンジオテンシン2受容体拮抗薬
  • β遮断薬
  • 利尿薬
  • アルドステロン拮抗薬
  • 強心薬
  • その他

第7章 市場内訳：投与経路別

  • 経口剤
  • 静脈内投与

第8章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH（C.H. Boehringer Sohn Ag & Co. KG）
    • Novartis AG
図表

List of Figures

  • Figure 1: Global: Congestive Heart Failure Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Congestive Heart Failure Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Congestive Heart Failure Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Congestive Heart Failure Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Congestive Heart Failure Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Congestive Heart Failure Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Congestive Heart Failure Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Congestive Heart Failure Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Congestive Heart Failure Drugs (Angiotensin 2 Receptor Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Congestive Heart Failure Drugs (Angiotensin 2 Receptor Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Congestive Heart Failure Drugs (Beta Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Congestive Heart Failure Drugs (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Congestive Heart Failure Drugs (Diuretics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Congestive Heart Failure Drugs (Diuretics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Congestive Heart Failure Drugs (Aldosterone Antagonists) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Congestive Heart Failure Drugs (Aldosterone Antagonists) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Congestive Heart Failure Drugs (Inotropes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Congestive Heart Failure Drugs (Inotropes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Congestive Heart Failure Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Congestive Heart Failure Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Congestive Heart Failure Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Congestive Heart Failure Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Congestive Heart Failure Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Congestive Heart Failure Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Congestive Heart Failure Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Congestive Heart Failure Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Congestive Heart Failure Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Congestive Heart Failure Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Congestive Heart Failure Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Congestive Heart Failure Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Congestive Heart Failure Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Congestive Heart Failure Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Congestive Heart Failure Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Congestive Heart Failure Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Congestive Heart Failure Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Congestive Heart Failure Drugs Market: Competitive Structure
  • Table 7: Global: Congestive Heart Failure Drugs Market: Key Players
目次
Product Code: SR112024A6649

The global congestive heart failure drugs market size reached US$ 8.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 22.6 Billion by 2032, exhibiting a growth rate (CAGR) of 11.17% during 2024-2032. The rising prevalence of obesity and cardiovascular problems, increasing geriatric population and unhealthy dietary habits represent some of the key factors driving the market.

Congestive heart failure is a medical condition that affects the pumping ability of the heart muscle. It is generally caused by hypertension, coronary artery disease, diabetes, obesity, and excessive alcohol consumption. Its symptoms include shortness of breath while lying down, weakness, fatigue, swelling in the abdomen, feet, and ankles, frequent urination at night, nausea, and difficulty in concentration. It can be prevented by maintaining a healthy weight, staying physically active, and controlling blood pressure and glycemic levels. Besides this, it is controlled using various prescribed drugs that help prevent blood clots, expand blood vessels, strengthen the contractions of the heart, and improve heart functioning. At present, ACE inhibitors, vasodilators, digitalis glycosides, diuretics, and beta-blockers are some of the most prescribed congestive heart failure drugs. Amongst these, ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals.

Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market. In addition, excessive smoking and drinking of alcoholic beverages, coupled with unhealthy dietary habits of individuals, increases the risks of heart problems, which is catalyzing the demand for congestive heart failure drugs across the globe. This, coupled with the rising occurrence of heart problems due to obesity and lack of physical activity, is currently strengthening the growth of the market. Furthermore, the increasing awareness among individuals about the benefits of early diagnosis and treatment of heart disease is creating a positive outlook for the market. Apart from this, the escalating demand for effective drugs and treatment and their approval from authorized agencies offer lucrative growth opportunities to the leading market players. Moreover, initiatives undertaken by governments of various countries to improve healthcare infrastructure and provide optimal care to patients are contributing to the growth of the market. Additionally, the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods are expected to propel the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global congestive heart failure drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration, and distribution channel.

Drug Class Insights:

ACE Inhibitors

Angiotensin 2 Receptor Blockers

Beta Blockers

Diuretics

Aldosterone Antagonists

Inotropes

Others

The report has also provided a detailed breakup and analysis of the congestive heart failure drugs market based on the drug class. This includes ACE inhibitors, angiotensin 2 receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, and others. According to the report, ACE inhibitors represented the largest segment.

Route of Administration Insights:

Oral

Intravenous

A detailed breakup and analysis of the congestive heart failure drugs market based on the route of administration has also been provided in the report. This includes oral and intravenous. According to the report, the oral route of administration accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the congestive heart failure drugs market based on the route of administration has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (The United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. According to the report, North America was the largest market for congestive heart failure drugs. Some of the factors driving the North America market included the development of healthcare infrastructure, increasing cases of heart failure and the easy availability of technologically advanced devices and innovative drugs.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global congestive heart failure drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Novartis AG, etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global congestive heart failure drugs market?
  • 2. What is the expected growth rate of the global congestive heart failure drugs market during 2024-2032?
  • 3. What are the key factors driving the global congestive heart failure drugs market?
  • 4. What has been the impact of COVID-19 on the global congestive heart failure drugs market?
  • 5. What is the breakup of the global congestive heart failure drugs market based on the drug class?
  • 6. What is the breakup of the global congestive heart failure drugs market based on the route of administration?
  • 7. What is the breakup of the global congestive heart failure drugs market based on the distribution channel?
  • 8. What are the key regions in the global congestive heart failure drugs market?
  • 9. Who are the key players/companies in the global congestive heart failure drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Congestive Heart Failure Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 ACE Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Angiotensin 2 Receptor Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Beta Blockers
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Diuretics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Aldosterone Antagonists
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Inotropes
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report